Review

Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy

Fangmin Chen\textsuperscript{a,1}, Yifan Fang\textsuperscript{a,1}, Xiang Chen\textsuperscript{a}, Rui Deng\textsuperscript{a}, Yongjie Zhang\textsuperscript{a}, Jingwei Shao\textsuperscript{a,b,*}

\textsuperscript{a} Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou, Fujian 350116, China
\textsuperscript{b} Institute of Oceanography, Minjiang University, Fuzhou 350108, China

\textbf{A R T I C L E   I N F O}

Article history:
Received 26 March 2020
Revised 1 July 2020
Accepted 25 July 2020
Available online 21 August 2020

Keywords:
Sorafenib
Multi-kinase inhibitor
Smart nanodelivery systems
Tumor microenvironment
Combination therapy

\textbf{A B S T R A C T}

Sorafenib, a molecular targeted multi-kinase inhibitor, has received considerable interests in recent years due to its significant profiles of efficacy in cancer therapy. However, poor pharmacokinetic properties such as limited water solubility, rapid elimination and metabolism lead to low bioavailability, restricting its further clinical application. Over the past decade, with substantial progress achieved in the development of nanotechnology, various types of smart sorafenib nanoformulations have been developed to improve the targetability as well as the bioavailability of sorafenib. In this review, we summarize various aspects from the preparation and characterization to the evaluation of antitumor efficacy of numerous stimuli-responsive sorafenib nanodelivery systems, particularly with emphasis on their mechanism of drug release and tumor microenvironment response. In addition, this review makes great effort to summarize the nanosystem-based combination therapy of sorafenib with other antitumor agents, which can provide detailed information for further synergistic cancer therapy. In the final section of this review, we also provide a detailed discussion of future challenges and prospects of designing and developing ideal sorafenib nanoformulations for clinical cancer therapy.

© 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Cancer is still a leading cause of mortality all over the world [1]. Statistics revealed that there were 18.1 million new cases and 9.6 million deaths of cancer in 2018.

Conventional chemotherapy as the main method for cancer therapy has achieved no significant advances over the past decades. One of the well-accepted disadvantages of chemotherapy is the lack of specificity, further leading to considerable damage to normal tissues [2]. Moreover, the primary or acquired resistance to chemotherapeutic drugs...
such as cisplatin, doxorubicin and 5-fluorouracil is often developed, which resulting in a significant reduction of the progression-free survival and overall survival rates of cancer patients [3]. In recent years, molecular targeted therapy has been successfully developed and demonstrated prospective profiles of efficacy in the front-line clinical treatment of human cancers [4,5]. Sorafenib, as one of the molecular targeted drugs, displays considerable activity in improving progression-free survival and overall survival rates of cancer patients in the clinic [6]. Accumulated mechanistic elucidation investigations revealed that the antitumor efficacy of sorafenib is attributed to its ability to suppress cell proliferation, induce cell apoptosis and prevent angiogenesis [7,8]. It was found that sorafenib triggers cell cycle arrest, autophagy and apoptosis by regulating various protein kinases and signal transduction pathways such as the signal transducer and activator of transcription 3 (STAT3), vascular endothelial growth factor receptor 2 (VEGFR-2) and platelet-derived growth factor receptor (PDGFR) [9,10]. For instance, sorafenib has been demonstrated to negatively regulate STAT3 activation by protein tyrosine phosphatases through de-phosphorylation of phosphorylated-p-STAT3 (p-STAT3), which leading to the down-regulation of expression levels of apoptosis-related proteins and genes such as cyclin D1, caspase-3, Mcl-1 and Bcl-2 [11,12]. In addition, it was also reported that sorafenib can block the development of solid tumors mostly through the inhibition of RAF/MEK/ERK signaling cascade [13,14].

Despite sorafenib displays significant profiles of efficacy for cancer therapy as compared to chemotherapeutic drugs, it should be noted that sorafenib still has some disadvantages in clinical therapy: (i) The clinical application of sorafenib is greatly limited by its low bioavailability (~8.43%), resulting from its poor water solubility and rapid elimination and metabolism [15]; (ii) A dose reduction or temporary discontinuation of sorafenib can be frequently observed in many cancer patients due to the serious side effects including skin toxicity, diarrhea, hypertension and hand-foot syndrome [16,17]. The chemical structure of sorafenib is presented in Fig. 1. From which we can find that soafenib is a hydrophobic drug, and the high hydrophobicity of sorafenib contributes to its effective encapsulation into various materials.

In order to overcome the above disadvantages to obtain desired delivery system of sorafenib with great advantages in the clinic, various types of stimuli-responsive sorafenib nanodelivery systems have been prepared and studied in great detail [18,19]. These smart sorafenib nanodelivery systems possess a number of advantages over traditional formulations such as the improved targetability and bioavailability, controlled drug release manner and enhanced tumor accumulation capacity [20]. It is noted that the critical advantage of sorafenib-based nanodelivery systems is that they are inactive before delivering into tumor tissues so that they can protect sorafenib from early leaking through the systemic circulation, thus reducing the occurrence of adverse events. Moreover, in addition to smart sorafenib nanoformulations, a series of combination nanosystems of sorafenib with other antitumor agents also have been prepared and found to display significantly enhanced therapeutic effect based on cooperative mechanism of antitumor actions [21]. In this review, great effort has been made to summarize the preparation methods, pharmaceutical properties and preclinical performance of various types of smart sorafenib nanodelivery systems including pH-, redox-, enzyme-, light-, temperature- and ultrasound-responsive nanosystems, particularly with emphasis on their mechanism of drug release and tumor microenvironment response. In addition, an emphasis is also placed on the nanosystem-based combination therapy of sorafenib with other antitumor agents such as chemotherapy agents, phototherapy agents and gene-therapy agents (Fig. 2). These combination nanosystems with multi-mechanism of antitumor actions were able to display satisfactory therapeutic outcomes, thereby could provide useful information for future synergistic cancer therapy. The overall information presented in this review is aim at providing an insight into the future challenges and prospects in the design and preparation of ideal sorafenib nanoformulations for clinical cancer therapy.

![Fig. 1 – Structure of sorafenib.](image)

**2. Representative materials in sorafenib nanodelivery systems**

Biomaterials techniques have achieved significant advances in recent years and which have been widely exploited to develop natural or synthetic materials for constructing the efficient drug delivery systems [22–25]. In order to improve the pharmacokinetic shortcomings, such as weak
water solubility, rapid elimination and metabolism as well as low bioavailability of sorafenib. Hence, various types of representative materials have been used to develop sorafenib delivery strategies. Among different representative materials, liposomes had the greatest potential to be clinically translated due to their unique advantages including good biocompatibility and biodegradability, low toxicity and immunogenicity [26]. Meanwhile, the high hydrophobicity and great lipid affinity of sorafenib could ensure the effective encapsulation of sorafenib into liposomes, which protected the drug from leaking into normal tissues and thereby reduced the adverse effects [27]. Solid lipid nanoparticles are another representative materials to be utilized for improve the safety and efficacy of sorafenib. In addition to show the similar advantages with liposomes, solid lipid nanoparticles are also featured with their great tumor targeting and controlled drug release properties through being modified with various functional ligands [28,29]. Poly(lactic-co-glycolic acid) (PLGA) is one of the representative polymeric materials and has been approved by FDA for clinically using in drug delivery strategies [30]. As a biocompatible and biodegradable polymer, PLGA has been widely used in drug delivery systems based on nanoparticles for sorafenib delivery [31]. The obtained PLGA nanoparticles had high drug loading capacity of sorafenib owing to its hydrophobic properties, and could achieve controlled release sorafenib into tumor tissues through surface-modified with tumor-targeting ligands or stimuli-responsive linkers [31]. Silica-based materials have attracted considerable attention for their application in drug delivery and nanomedicines preparation. The outstanding advantage of silica-based materials is their large surface area and pore volume [32], contributing to the high drug loading efficiency of sorafenib. Moreover, silica-based materials are easy to be surface-modified with various stimuli-responsive linkers and thereby serve as targeted delivery systems for co-delivery of sorafenib with chemotherapeutic agents [33]. As presented above, we summarized and discussed the representative materials that constructing the delivery systems for sorafenib. The selection of materials to be used for sorafenib delivery is essential to the clinical translation of sorafenib formulations. With aim at promoting the clinical success of sorafenib nanof ormulations, we should carefully consider the surface characteristics, biosafety, targetability, preparation procedure and manufacturing cost of various materials that used for sorafenib delivery.

3. Development of smart sorafenib-based nanodelivery system

Over the past decades, various types of traditional sorafenib nanodelivery systems such as liposomes [34,35], solid lipid nanoparticles [36,37], polymeric nanoparticles [38,39] and micelles [40,41], gold nanoparticles [42] and inorganic nanoparticles [43] have achieved significant enhancement in therapeutic effect as compared to free sorafenib. However, the overall evidence suggested that the traditional sorafenib nanodelivery systems still need to overcome some shortcomings or challenges including inadequate targetability, uncontrolled drug release and non-guided blood circulation. Hence, there is an urgent demand to design and fabricate a series of improved nanodelivery systems to further enhance the sorafenib delivery into tumor sites. Accumulating evidence demonstrated that an ideal nanodelivery system should be sensitive to tumor microenvironment and subsequently release its payload at the most into tumor tissues, thereby leading to a more satisfactory therapeutic outcome in cancer therapy. Taking this into account, developing smart nanodelivery systems with stimuli-responsive ability are highly needed for enhanced cancer therapy. In recent years, various endogenous stimuli including pH, glutathione (GSH), matrix metalloproteinases (MMPs) or external stimuli including light, temperature and magnetic field have been addressed to prepare smart responsive delivery systems for tumor-targeted sorafenib delivery.

3.1. pH-responsive sorafenib-based nanodelivery systems

pH-responsive drug delivery systems are sensitive to the abnormal change of pH values in diseased tissues and it have been widely explored for targeted drug release [44,45]. Studies revealed that the pH values of tumor microenvironment is frequently lower than normal tissues [46], indicating that developing pH-responsive sorafenib delivery systems could become effective strategies to display improved tumor targetability and controlled release manner in cancer therapy. For instance, Liu et al. reported on the encapsulation of sorafenib into m-polyethylene glycol -PLGA-poly(L-phenylalanine) (PEG-PLGA-PPA) micelles via the ring opening polymerization. It was showed that the hydrophobic drug can assemble in the hydrophobic block copolymers forms the core of micelles [47]. The in vitro release efficiency of sorafenib from micelles could be improved by regulating the hydrophilic/hydrophobic ratios of the triblock copolymers. The pH-responsive sorafenib micelles displayed significantly higher antitumor effect than free sorafenib while the empty micelles demonstrated no cytotoxicity [48]. Their results were in congruence to those of Li et al. as a novel pH-responsive polymeric micelle was synthesized [49]. It was found that the amide bond and CDM bond of this micelle were able to rapidly break on the weak-acid conditions, which led to the depolymerization of micelle, thereby displaying a pH-responsive sorafenib release manner and an enhanced tumor selectivity. The half-life of this sorafenib-loaded micelle was extended to 36.7 h and of free sorafenib was only 8.8 h. The obvious long circulation effect of this micelle was arise from its significant sustained release effect under physical conditions. Meanwhile, the good physical stability of the micelle also promoted the long circulation of sorafenib in vivo. Inspired by such advantages discussed above, Thapa et al. made great efforts on the preparation and evaluation of a pH-responsive layer-by-layer liquid crystalline nanoparticle of sorafenib (Fig. 3). This nanosystem was able to efficiently release sorafenib at acidic tumor microenvironment due to the selective depolymerization of polymer layers and then facilitated subsequent intracellular uptake of released sorafenib, thereby leading to an enhanced antitumor efficacy against HepG2 cells [19]. Further, Yao et al. developed a pH-triggered liposome, in which sorafenib and siRNA were
3.2. Redox-responsive sorafenib-based nanodelivery systems

It is recognized that the cellular redox environment is mainly regulated by the concentration of GSH. As one of the thiol-containing tripeptides, GSH is abundant in cancer cells while has a low concentration in normal cells [52,53]. Some linking bonds between the amphiphilic polymers were found to be responsive to reductive GSH, indicating that the GSH could act as a stimulus to effectively trigger drug release from nanosystems. In addition, it was reported that sorafenib could block cysteine (Cys)/glutamate (Glu) reverse exchanging system and increase the level of reactive oxygen species (ROS) in cancer cells, therefore, GSH will be reduced [54]. Moreover, many researchers reported that the deletion of intracellular GSH would ultimately lead to the ferroptosis of cells [55]. Based on the above research, it was showed that exhaustion of the intracellular GSH in dual directions could exert a superior ferroptosis-inducing effect. Therefore, a variety of GSH-responsive nanodelivery systems have been successfully synthesized for controlling the release of sorafenib into tumor tissues [56,57]. In a work by Liu et al., the amphiphilic polymers poly (acrylic acid) (PAA) linked with D-α-tocopherol succinate (VES) by disulfide linkage and which can self-assemble into micelles suitable for sorafenib delivery. The micelles were found to effectively improve the aqueous solubility of sorafenib and control its release. In addition, owing to the GSH-sensitivity of disulfide linkage, a controlled and GSH-dependent drug release manner could be observed from the micelles group, which contributed to its enhanced cytotoxicity. In vivo pharmacokinetics studies demonstrated that the sustained release profile of sorafenib from the GSH-responsive micelles could improve the half-life and AUC values of sorafenib, and which were about 1.3 and 2.8-fold higher than free sorafenib, respectively [58]. In another study, a series of manganese doped mesoporous silica nanoparticles (MMSNs) have been synthesized and utilized as delivery vehicles of sorafenib. In addition, the sorafenib was loaded into MMSNs by physical adsorption. The structure of MMSNs contains some manganese-oxidation bonds and which could rapidly break under high GSH concentration conditions, subsequently leading to the degradation of MMSNs. Therefore, a GSH-responsive drug release manner could be achieved in MMSNs and its in vitro inhibitory effect was significantly enhanced via the consumption or synthesis inhibition of GSH [59]. Inspired by the above results, Sang et al. developed a sorafenib-loaded nanophosensitizer complex for the ferroptosis of multi-drug resistant cancer cells. This nanocomplex with disulfide bonds could be triggered in the presence of GSH stimuli, and simultaneously produce ROS, iron and raise the concentration of lipid peroxidation (LPO), thus resisting the multi-drug resistance, invasion and metastasis of breast cancers during the epithelial-to-mesenchymal transition (EMT) (Fig. 4) [60]. These studies presented smart nanodelivery systems that effectively enhance the effect of cancer therapy through GSH-responsive sorafenib delivery. These GSH-responsive nanodelivery systems exhibited enhanced antitumor activity and fewer side effects as compared to free sorafenib, showing great potential for inhibiting cancer progression. However, the specific GSH-responsive drug release mechanism has not been illustrated in most studies, and this challenge must be addressed before the GSH-responsive delivery systems can be accepted for clinical use. In addition, the excess GSH in the tumor microenvironment would scavenge the cell-killing ROS during the therapeutic process, leading to the failure of ROS-mediated cancer therapy. Thus, combining the GSH depletion agents with sorafenib therapy can be developed as effective strategies to enhance cancer therapeutic outcomes.
Fig. 4 – GSH-triggered magnetic complex of sorafenib and nanophotosensitizer (CSO-SS-Cy7-Hex/SPION/Srfn) for the comprehensive ferroptosis therapy. (A) Schematic illustration for the preparation of CSO-SS-Cy7-Hex/SPION/Srfn. (B) Sorafenib release profiles at different light or GSH conditions. (C) Iron release profiles at different light or GSH conditions. (D) Tumor sizes with time after different treatments. Adapted with permission from [60]. Copyright 2019, Ivyspring International Publisher.

Fig. 5 – MMP-2-responsive nanoparticles for synergistic antitumor effect of anti-angiogenesis and chemotherapy. (A) Schematic illustration of the co-assembly and disassembly of nanoparticles subject to MMP-2 stimuli. (B) Accumulative release of drug from nanoparticles in different media. (C) Tumor sizes with time after different treatments. (D) In vivo biodistribution of tumor-bearing mice after administration of Cy5.5 loaded nanoparticles and free Cy5.5. Adapted with permission from [64]. Copyright 2016, American Chemical Society.

3.3. Enzyme-responsive sorafenib-based nanodelivery systems

Accumulating evidence has demonstrated MMPs, especially MMP-2 and MMP-9 were over-expressed in various types of tumor microenvironment [61]. MMPs were found to be highly correlated with tumor metastasis, invasiveness and angiogenesis [62,63]. Therefore, a variety of smart nanodelivery systems which could be respond to MMPs have been designed to enhance the drug delivery into tumor tissues. In a recent work by Shi et al., a novel MMP-2 responsive nanodelivery system which self-assembled from amphiphilic mPEG-peptide deblock copolymer (PPDC), then sorafenib and camptothecin be co-loaded into the core area through hydrophobic interaction (Fig. 5). Upon exposure to tumor microenvironment, the peptide segments could be digested by MMP-2 and then simultaneously release two drugs into tumor tissues. It was found that sorafenib delivered by the MMP-2 responsive systems could retain at a higher concentration in the bloodstream as compared to free sorafenib. The longer retention time of sorafenib nanosystems promoted the improved drug accumulation in tumor tissues. Moreover, this nanosystem displayed an enhanced therapeutic effect for tumor suppression through the synergistic actions of simultaneous anti-angiogenesis and chemotherapy [64].

The representative example highlighted the potential of enzyme-responsive nanodelivery systems for tumor-specific sorafenib-delivery. Nevertheless, the information of enzyme levels in tumor tissue is still need to be further explored, maybe some of which act as a stimulus to trigger the precise release of drug from nanosystems.

3.4. Temperature-responsive sorafenib-based nanodelivery systems

In addition to endogenous stimuli such as pH values, GSH and MMPs, the external stimuli such as temperature has also been considered as a promising stimulus for thermal responsive drug delivery based on thermosensitive polymers [65]. Polypropylene oxide (PPO), polycaprolactone (PCL), PEG and PLGA as the ideal thermosensitive polymers with tunable critical solution temperature in water, have been widely utilized as thermosensitive delivery materials for localized and sustained drug release [66,67]. For instance, Zheng et al. developed a PLGA-PEG-PLGA-based thermosensitive nanosystem in order to control the release profiles of sorafenib and selenium nanoparticles. The results showed that sorafenib was released continuously with the temperature-dependent degradation of the copolymers for a prolonged time. Under the X-ray irradiation, the
the great prospects for enhancing targeted drug release by using gold nanorod-based temperature-responsive delivery systems. Inspired by the delivery efficiency of human serum albumin protein (HSAP) nanoparticle towards cancer cells [73,74], Callaghan et al. designed a HSAP-modified gold nanorod of sorafenib to induce a temperature-triggered chemo-photothermal therapy. This nanoplatform was found to display triggered release of sorafenib and synergistic inhibitory effect against cancer cells [75]. Considering that the thermosensitive nanodelivery systems can be triggered by the hyperthermia effect induced by phototherapy, a thermosensitive nanosystem-based combination of sorafenib with phototherapy agents may of great potential for enhanced cancer therapy. The challenge in the design of temperature-responsive nanosystems is the selection of safe and sensitive materials to be respond to slight temperature changes around physiological temperature. Among the most investigated temperature-responsive materials, liposomal carriers are approved by FDA and have wide clinical applications, therefore, it could be used as a preferred nanocarrier.

3.5. Ultrasound-responsive sorafenib-based nanodelivery systems

Among the external stimuli, ultrasound is particularly attractive due to its superior ability to induce bubble cavitation and subsequently facilitate drug release, enhance cellular uptake and affect tumor microvasculature [76]. Ultrasound displays great potential to simultaneously improve local therapeutic effect as well as tumor contrast imaging [77]. Yang’s group pioneered the development of ultrasound-triggered phase transition nanodroplets for co-delivering sorafenib and doxorubicin. Upon exposure to ultrasound irradiation, the nanodroplets occurred a liquid-to-gas phase transition, which could be served as a cavitation nucleus to promote drug release and enhance cellular uptake. In vitro studies using liver cancer cells revealed that the nanodroplets could effectively inhibited cell proliferation, migration and induced apoptosis. Further, the strong cavitation of drug-loading nanodroplets could significantly disrupt tumor microvessels, which was beneficial for tumor tissue-penetrating drug delivery and consequently led to reduced tumor angiogenesis and inhibited tumor growth in tumor bearing mice [78]. Under the ultrasound irradiation, the average tumor volume of drug-loaded nanodroplets was 417 ± 132 mm³ and the inhibition rate was increased up to nearly 68.7%. Ultrasound waves utilized the thermal and mechanical effects generated by radiation forces resulted in triggering drug release. Additionally, it was noteworthy that combination of thermosensitive carriers and high-intensity focused ultrasound triggered the release of drug with only a mild temperature change, indicating that the construction of temperature and ultrasound multi-responsive nanodelivery systems may have potential for improving the therapeutic outcomes of sorafenib.

3.6. Dual/multi-responsive sorafenib-based nanodelivery systems

Recently, multi-responsive nanodelivery systems based various endogenous/external stimuli have been explored.
to display synergistic enhancement of drug delivery in cancer therapy. As an example, Park et al. reported a dual-responsive nanosystem which composed of iron oxide nanocube and pH-sensitive peptides for targeted delivery of sorafenib. This nanosystem with magnetic properties was responded to acidic tumor microenvironment, which led to a MRI-guided and pH-triggered drug release manner, and subsequently displayed an enhanced tumor growth inhibition in HCC models [79]. In addition to the traditional apoptotic therapeutics mean, ferroptosis is also widely applied in cancer therapy [80,81]. It is an iron-dependent cell death caused by accumulation of LPO and is highlighted with clinical significance for tumor treatments [82,83]. In order to improve the therapeutic outcomes of current ferroptosis therapy, IR780-Hex, magnetic iron oxide nanoparticles and sorafenib were co-loaded into a novel multi-stimuli responsive nanosystem. This system disassembled by the GSH attack and triggered by the NIR irradiation to release payloads for the production of LPO and synergistic effects to improve therapeutic efficacy in the breast tumor-bearing mice [84]. Moreover, Liu’s group designed a ferrous-supply-regeneration nanosystem compose of Fe^{3+}, derived tannic acid (TA) and sorafenib nanocrystal. Studies revealed that pH declines could destroy the nanosystem followed by the corona erosion, leading to the rapid release of sorafenib into tumor cells to initiate ferroptosis. In addition, this network could be modified with a photodynamic agent of methylene blue (MB) to display significant photodynamic effect and tumor imaging ability. This imaging-guided and acid-responsive system could induce complete tumor elimination through the simultaneous actions of photodynamic therapy (PDT) and ferroptosis therapy (Fig. 7) [85]. Despite the advantageous versatility of these multi-responsive sorafenib-based nanodelivery systems, it is noted that these nanosystems often appear so complex that they are still developed at the proof-of-concept level. Therefore, more studies and investigations should be carried out to prove that these multi-responsive nanosystems were viable strategies.

3.7 Imaging-guided smart sorafenib nanodelivery systems

In recent years, great attention has been paid in the development of nanoparticle-based theranostic strategy for simultaneous cancer therapy and imaging [85]. For instance, a liposomal delivery system composed of sorafenib and gadolinium was prepared to serve as not only a therapeutic agent for HCC therapy, but also a contrast agent for magnetic resonance imaging (MRI). The in vivo efficacy demonstrated that the liposome displayed the highest antitumor effect in H22 tumor-bearing mice [86]. In addition, superparamagnetic iron oxide nanoparticle (SPION), as a MRI contrast agent, was co-load with sorafenib into solid lipid nanoparticles to enhance the sorafenib delivery with the guidance of remote MRI imaging, which subsequently led to the comprehensive antitumor effect against HepG2 cells [87]. Moreover, surface-modification of nanoparticles with specific ligands to recognize cancer cell receptors could further improve its tumor active targetability [88]. Zhang et al. developed a folate-modified micelles based on PEG-PCL polymer, in which sorafenib and SPIONs were co-loaded. The targeted micelles possessed significant effect in inhibiting proliferation and inducing apoptosis of cancer cells in vitro [89]. Melanin, as a naturally occurring pigment, not only can offer its intrinsic property for PAI, but also is able to actively chelate to metal ions for MRI and positron emission tomography (PET) [90]. Inspired by this, Zhang’s group pioneered the development of PEG-modified melanin delivery system of sorafenib (SF-MNPs) to realize imaging-guided chemotherapy. The melanin-based system displayed a gradual drug release manner and subsequently caused a significant tumor volume reduction of mice (Fig. 8) [91]. As compared to the traditional imaging-guided nanodelivery systems that need complicated modification and introduce contrast agents of potential toxicity, SF-MNPs as natural platforms are more preferable to simplify the preparation procedure for safe imaging-guided sorafenib therapy. Moreover, considering melanin is
combination delivery systems are considered to be of great potential to overcome the issues of drug resistance, as synergistic actions of multiple agents may improve the tumor cell killing activity and also decrease the toxicity toward normal cells [93]. Accumulated evidence have demonstrated that sorafenib can inhibit the expression of VEGFR and PDGFR as well as block the cell signaling pathway mediated by RAF/MEK/ERK to inhibit the proliferation of tumor cells [9,10]. However, there are some compensation signaling pathways existing in tumor progression so that tumor cells can escape from the signaling pathway blockade mediated by sorafenib, thus leading to an unsatisfactory therapeutic outcomes in some cancer patients. Moreover, high-dosage use of sorafenib in clinic has caused obvious drug resistance issues in some patients, thus combining sorafenib with its antitumor analogues or adjuvant agents can also display synergistic therapeutic effect based on cooperative mechanism of actions. Inspired by this, a series of composite nanosystems of sorafenib with other antitumor agents such as chemotherapy agents, immune-modulating agents, phototherapy agents and gene-therapy agents have been developed.

4.1. Composite nanosystems of sorafenib with chemotherapy agents

Co-administration of sorafenib with other chemotherapeutic agents has been widely studied for improved therapeutic effect in cancer therapy. Doxorubicin as a commonly used antitumor drug can exhibit significant antitumor efficacy through intercalating DNA as well as inhibiting topoisomerase II preventing DNA replication [94]. Due to the complementary mechanisms of sorafenib with doxorubicin, there is interest in combination treatments with the two drugs to display synergistic antitumor effect. In a phase II clinical trial, the combination therapy of sorafenib and doxorubicin led to a significant improvement on the median overall survival of advanced HCC patients [95]. Xiong’s group developed a reduction-responsive nanodelivery system for loading sorafenib and disulfide-modified doxorubicin prodrug. In this system, sorafenib was delivered with PEG-b-cyclodextrin (PEG-b-CD) amphiphiles in the core of polymeric nanoparticle by hydrophobic interaction and π-π stacking interaction with doxorubicin. This nanosystem could be triggered by dithiothreitol and subsequently displayed enhanced cytotoxicity against HepG2 cells than physical mixtures of sorafenib and doxorubicin [96]. Still, more detailed in vivo results need to be achieved for evaluating the prospect of this co-delivery strategy. A core-shell lipid-based nanosystem has been prepared by Malavizhi et al. for improving the tumor co-accumulation of sorafenib and doxorubicin. The core-shell nanoparticle effectively imparted cytotoxic stress and displayed synergistic cytotoxic effect against 92% of tested HCC cells [97]. The similar synergistic effect also could be achieved in Lei et al.’s work, in which sorafenib and paclitaxel were co-loaded into a multifunctional liposome with modification by hyaluronic acid (HA). Paclitaxel can promote tubulin polymerization and microtubule assembly so that stabilize microtubules and inhibit mitosis of tumor cells, thus triggering cell apoptosis, and effectively preventing

an endogenous biopolymer, the melanin-based system may have great potential to efficiently deliver other antitumor agents for further multimodality-imaging guided cancer therapy.

The various stimuli-responsive sorafenib nanodelivery systems were summarized in Table 1. The current stimuli-responsive sorafenib-based systems have limited chances of being applied in the clinic due to absence of insufficient biocompatibility or degradability. The ability of these systems to be sensitive to discrete change of pH, GSH, enzyme or temperature potential is not straightforward to achieve, and the penetration depth of exogenous stimulus into targeted tissues also should be addressed. For most of these systems, the difficulties in the scaling-up of their synthesis and complexity of their architectural design are likely to hinder their clinical translation. It is hard to indicate which stimuli-responsive nanosystems have the most potential to be used in the clinic. Thus, the simpler and easier system is developed, the better its potential to be used in the clinic. Numerous progress in nanotechnology has promoted the development of smart sorafenib-based nanodelivery system. In the future days, perhaps we should pay more attention on the clinically acceptable nanodelivery systems that are more sensitive to discrete variations in specific stimuli.

4. Development of combination therapy of sorafenib

Over the past few years, combination delivery of different therapeutic agents using nanosystems have emerged as prospective strategies for enhanced cancer therapy [92]. These

Fig. 8 - Ultra-small PEG-modified melanin nanoparticles (SF-MNPs) as imaging-guided delivery systems for enhanced chemotherapy. (A) Schematic illustration of the process of imaging-guided tumor therapy by SF-MNPs. (B) Visual illustration of tumor development of tumor-bearing mice after different treatments. (C) Tumor growth curves of tumor-bearing mice after Adapted with permission from. Reproduce with permission [91], Copyright 2015, WILEY-VCH.
the proliferation of cancer cells [98]. HA was found to directly bind to CD44 receptor which over-expressed on cancer cells, thereby leading to the attractive applications of HA-modified liposomes for active targeting of sorafenib [99,100]. The modified liposome demonstrated an endo-lysosomal escape in the tumor microenvironment, leading to high drug co-accumulation and improved cancer therapeutic outcome [101]. The liposomal nanosystems have also been applied for the efficient co-delivery of sorafenib and ceramide for enhanced cancer therapy [102]. Further, Zhang et al. developed a nanoscale co-delivery system of sorafenib and cisplatin. This system displayed great pH-sensitive

| Stimuli responsive | Structure | Mechanism of drug release | Observations | Ref. |
|--------------------|-----------|---------------------------|--------------|-----|
| pH                 | Micelles constructed using HES-TG100–115 and PEG-CDM polymers | Low pH conditions caused the depolymerization of micelles due to the sensitivities of amide bond and CDM bond | In vivo studies showed a higher level of antitumor efficacy and better tolerance against mice with Hep-3B cells | [143] |
| pH                 | Liquid crystalline nanoparticles assembled from layer-by-layer polymers | A phase inversion of LCN occurred in acid conditions | Nanoparticles had significantly higher cytotoxicity to HepG2 cells than free drug | [19] |
| pH                 | Liposomes functionalized with CMCS | The CMCS which bearing -COOH and -NH2 could become positively charged at acidic environment. | In vivo studies showed enhanced antitumor efficacy of liposomes as compared to free sorafenib | [50] |
| GSH                | Micelle constructed by linking PAA with VES via a disulfide bond linker. | Cleavage of the disulfide bonds occurred in a reductive environment. | Cytotoxicity assay using BGC-823 cells showed higher cytotoxicity as compared to free sorafenib | [58] |
| GSH                | MSN doped with manganese-oxidation bonds. | Manganese-oxidation bonds of nanoparticles could break in the presence of high GSH concentration. | In vitro studies, this nanoparticles had a significant tumor suppression effect for HepG2 cells. | [59] |
| MMPs               | Nano system self-assembled from PPDC | The peptide segments would be digested by the overexpressed MMP-2. | In vivo studies in HT-29 tumor-bearing mice demonstrated enhanced therapeutic effect. | [64] |
| Light              | Nanosystems composed of gold nanorod cores and polyacationic mesoporous silica shells. | Under NIR light irradiation, the gold nanorod cores could trigger the drug release by opening the polycation cloak. | In vivo studies using hepatoma-bearing mice showed its significant synergistic antitumor effects after NIR irradiation. | [70] |
| Light              | HSA nanoparticles functionalized with gold nanorods. | The denaturation of HSA crosslinking secondary occurred after light irradiation. | Under light irradiation, nanoparticles could induce significant hyperthermias and further enhance cytotoxicity to kill RCC 786-O cells. | [75] |
| Temperature        | Polymeric system constructed from block copolymers of PLGA-PEG-PLGA. | The copolymers are in a sol-state at low critical solution temperature but will turn into the gel-state when at high temperature. | In vivo studies showed site-specific and long-term antitumor efficacy by using this thermosensitive drug-loading system | [39] |
| Ultrasound         | Phase transition perfluorcarbon liquid nanodroplets. | The release behavior of nanodroplets are correlated with its inertial cavitation process | Under ultrasound irradiation, the nanodroplet significantly inhibited the migration and invasion of tumors in vivo | [78] |
| Magnetic field     | PEG-functionalized ultrasmall melanin nanoparticles. | The slow in vivo degradation rate of melanin nanoparticles ensured its long-lasting integration. | In vivo studies showed the nanoparticles exhibited significant higher tumor inhibition as compared to free sorafenib. | [91] |
| pH, Magnetic field | Nanocomposite composed of iron oxide nanoparticles and pH-sensitive synthetic peptides. | At acidic environment, synthetic peptides will destabilize due to the ionization of imidazole groups. | This nanocomposite showed significant tumor growth inhibition in rodent HCC models. | [79] |
| GSH, Light         | Nanoparticles self-assembled from chitosan oligosaccharide-connected black hole quencher -IR780-Hex nanophotosensitizer | The ether bond between black hole quencher and IR780 was a response to GSH | This nanoparticle showed an excellent tumor accumulation ability and effectively inhibited tumor growth in breast tumor mouse models | [84] |
property due to the chelation interactions between HA and cisplatin, which guaranteed the major drug release and valid drug co-accumulation into tumor sites [103]. Increasingly attention has been paid on the nanoencapsulation of sorafenib with natural antitumor agents for combination cancer therapy. As an example, Cao et al. reported the design and development of nanoparticle which self-assembled from sorafenib, curcumin and PEGylated vitamin-E succinate (PEG-VES) through the hydrophobic interactions. Curcumin not only modulates a range of signaling pathways such as the NF-κB, TGF-β and JAK/STAT pathways in tumor cells, but also confers properties of electron receptors to destabilize ROS, thus displaying anti-apoptotic and antioxidant effects [104]. The nanoparticle could improve cytotoxicity and cell apoptosis in vitro, enhance drug tumor co-accumulation, and obviously suppress tumor progression with enhanced inhibitory effect [105]. Asialoglycoprotein receptor (ASGPR) is one of the over-expressed C-type lectin receptors (CTLR) in liver cancer cells [106]. Tunki et al. prepared a galactose-modified solid lipid nanoparticle of sorafenib, which not only showed enhanced cellular uptake and cytotoxic activity against ASGPR over-expressed HepG2 cells, but also displayed improved bioavailability in tumor-bearing mice as evidence from its higher mean residence time and AUC [107]. In addition, a MSN decorated with chitosan and lactobionic acid was utilized to co-load sorafenib and ursolic acid for targeting ASGPR over-expressed cancer cells, which subsequently displayed superior activities in inducing apoptosis, inhibiting cell migration, proliferation, angiogenesis against cancer cells (Fig. 9) [33]. Based on these observations, we conclude that developing composite nanosystems of sorafenib with chemotherapy agents can display synergistic antitumor effect due to their complementary mechanisms of action. The combination therapy strategies are beneficial to reduce the dosage of one single drug and overcome the drug resistance issues. It is noted that stimuli-activatable drug delivery systems have great potential to enhance drug accumulation into tumor tissues and thereby improve therapeutic outcomes. Thus, tumor microenvironment-targeted co-delivery of sorafenib with chemotherapy agents using stimuli-activatable nanoparticles may further enhance antitumor efficacy.

4.2. Composite nanosystems of sorafenib with immune-modulating agents

In recent years, immune-modulating agents have attracted much attention in cancer therapy due to their outstanding ability to inhibit tumor progression through modulating the immune system [108]. It is noted that the PD-L1 expression in tumor-infiltrating immune cells was increased after sorafenib treatment, indicating that sorafenib monotherapy may promote the development of tumor immunosuppression microenvironment and thereby inhibit the ability of immune systems to identify and attack tumor cells [109]. Based on these observations, a variety of combination therapy strategies of sorafenib with immune-modulating agents have been developed with aim at improving cancer therapeutic outcomes through simultaneously blocking tumor progression-relevant signaling pathways and boosting antitumor immune responses. C-X-C receptor type 4 (CXCR4)-targeted nanoparticles have attracted great interests in recent years as they preserving the properties of regulating tumor microenvironment, overcoming drug resistance and PD-L1-mediated immunosuppression [110,111]. Gao’s group exploited CXCR4-targeted nanoparticles to co-deliver sorafenib and CXCR4 antagonist AMD3100 for combination therapy. The targeted nanoparticles could effectively reduce infiltration of Tumor-associated macrophages (TAMs), enhance anti-angiogenic effect, inhibit tumor progression and improve overall survival in the HCC models [31]. CXCR4-targeted nanoparticles also exhibited satisfactory co-delivery outcomes of sorafenib and selumetinib for preventing the activation of RAF/ERK, down-regulating PD-L1 expression and facilitating infiltration of CD8+ T cells, subsequently inhibiting the development and progression of fibrosis-associated HCC [112,113]. In another study, anti-PD-1 antibody and sorafenib were co-loaded into CXCR4-targeted nanoparticles to further prevent the suppression of immune cells function in tumors through blockade of both CXCR4 and PD-1 pathway. This multi-drug delivery strategy displayed enhanced immune cell tumor penetration and activation, and ultimately delayed tumor development and progression (Fig. 10) [110]. TAMs are essential components of tumor microenvironment and which can promote tumor initiation, growth and metastasis by inhibiting immune cells [114,115]. In order to reverse phenotype of TAMs and display synergistic effects of chemotherapy and immunotherapy, Wang et al. developed a twin-core–shell nanoparticle for co-delivering sorafenib and TAM2 re-polarization agent IMD-0354. In Hepa1–6

Fig. 9 – Chitosan and lactobionic acid dual-functionalized mesoporous silica nanoparticles (MSN) for simultaneous drug delivery. (A) Schematic diagram of the preparation of dual-functionalized MSN. (B) Schematic illustration of the synergistic effect induced by the dual-functionalized MSN. (C) Visual illustration of tumor sizes after different treatments. (D) Time-dependent growth curves after different treatments. Adapted with permission from [33], Copyright 2017, Elsevier.
tumor bearing mice, this nanoparticle could exhibit superior synergistic antitumor effect and TAM$_2$ polarization ability [116]. In addition, a tumor microenvironment-responsive micelle system has been designed for the combination therapy of sorafenib and PI3K$_	ext{V}$ inhibitor TG100–115. It was found to effectively activate adaptive immunity and further exhibit enhanced antitumor effect in tumor-bearing mice [49]. Taking tumor hypoxia-directed nanoparticles as vehicles, Alsaab et al. fabricated a targeted co-delivery system of sorafenib with a class of apoptosis inducer CA IX-C4.16, which provided multimodal antitumor effects including the resuscitation of apoptosis, repolarization of TAM$_2$ and reversal of multi-drug resistance. Moreover, owing to the proper physical-chemical properties of CA IX-oligomer, this nanosystem could be further explored for diagnostic use and image-guided cancer therapy [117]. The overall evidence demonstrated that the combination strategies of sorafenib with cancer immunotherapies could show enhanced antitumor efficacy. However, in order to achieve clinical use of these combination strategies, the more biocompatible materials should be developed to safely and precisely deliver agents into desired sites. Moreover, the specific synergistic mechanisms of action between sorafenib with most immune-modulating agents are still unclear, and more efforts should be further paid on these settings.

4.3. Composite nanosystems of sorafenib with phototherapy agents

Recent studies suggested that sorafenib could enhance ROS generation, which implies that redox mechanism may also contribute to its antitumor efficacy. PDT is a newer class of cancer therapy that can produce a great amount of ROS upon light irradiation, and subsequently kill cancer cells and inhibit tumor development [118–120]. Moreover, some of phototherapy agents have the ability to induce significant photothermal effect upon light irradiation and subsequently lead to temperature change of delivery systems. Therefore, designing temperature-responsive materilas to co-delivery sorafenib with phototherapy agents may achieve tumor-specific drug release. Based on this concept, various nanodelivery systems have been widely used as co-delivery strategies for the combination therapy of sorafenib and phototherapy agents in order to exhibit synergistic therapeutic effect [93,121,122]. For example, a series of self-imaging polymeric nanoparticles have self-assembled from Pluronic F127, indocyanine green (ICG) and sorafenib through
the one-step nanoprecipitation method. Upon exposure to NIR laser irradiation, ICG could generate a great amount of ROS and hyperthermia to produce photothermal effect and simultaneously promote sorafenib for rapid release into tumor tissues, thereby resulted in synergistic and improved cytotoxic effects (Fig. 11) [123]. With aim at synergistic cancer therapy, Wei et al. synthesized a multifunctional nanoparticle of sorafenib and chlorin e6 (Ce6) through a reprecipitation technique. The nanoparticle with great passive targetability could efficiently cut off the tumor blood vessels and simultaneously kill tumor cells at a lower dosage in vivo (200 mg/kg), which demonstrating the significant

### Table 2 – A summary of various composite nanosystems of sorafenib with other agents.

| Drug-loaded | Structure | Therapies | Observations | Ref. |
|-------------|-----------|-----------|--------------|------|
| Sorafenib/Doxorubicin | Nanoparticle constructed from PEG-b-CD amphiphiles. | Chemotherapy/Chemotherapy | In vitro studies showed that the nanoparticles had stronger inhibitory effect against HepG2 cells as compared to the physical mixtures of two drugs group. | [96] |
| Sorafenib/Doxorubicin | Nanoparticle using PVA as the nano-core and HSA as the nano-shell. | Chemotherapy/Chemotherapy | This core-shell nanoparticle showed enhanced cellular uptake and synergistic cytotoxicity in ~92% of HCC cells. | [97] |
| Sorafenib/Paclitaxel | HA functionalized liposomes with TPGS and PLL-DA co-modifications. | Chemotherapy/Chemotherapy | The liposome demonstrated an enhanced antitumor effect in vivo, with a tumor growth inhibition rate of 78.52%. | [101] |
| Sorafenib/Cisplatin | Nanoparticles constructed by crosslinking HA with cisplatin. | Chemotherapy/Chemotherapy | The nanoparticles displayed synergistic tumor-killing effects after prolonged circulation time valid tumor accumulation | [103] |
| Sorafenib/Ursolic acid | A chitosan and lactobionic acid co-modified MSN. | Chemotherapy/Chemotherapy | In vivo studies showed significant tumor burden decrease and lung metastasis inhibition of the nanoparticle in H22 tumor-bearing mice model. | [33] |
| Sorafenib/IMD-0354 | Lipid-based twin-like core–shell nanoparticles. | Chemotherapy/Immunootherapy | In vivo studies showed the superior synergistic antitumor efficacy and M2-type TAM polarization ability of twin-like core–shell nanoparticles as compared to free sorafenib. | [116] |
| Sorafenib/CA IX-C4.16 | Nanoparticles which comprised of vitamin-E-α-D-tocopherol and styrene maleic anhydride. | Chemotherapy/Immunotherapy | Significant tumor accumulation and higher tumor growth inhibition of the nanoparticles were observed in mice models. | [117] |
| Sorafenib/AMD3100 | CXCR4 antagonist (AMD3100)-modified lipid–PLGA nanoparticles. | Chemotherapy/Immunotherapy | It displayed enhanced antiangiogenic effect and delayed tumor progression in the HCC models as compared to control groups. | [31] |
| Sorafenib/AMD3100/anti-PD-1 antibody | AMD3100-modified nanosystems which loading with sorafenib and anti-PD1 antibody. | Chemotherapy/Immunotherapy | This nanosystem effectively blocked the pathways of CXCR4 and PD-1, which prevented suppression of immune cells function in tumors. | [110] |
| Sorafenib/Indocyanine | A Pluronic F127-shielding carrier-free nanodrug. | Chemotherapy/PDT | The nanoparticles had improved stability and bioavailability and could specifically target tumor tissues via the EPR effect in vivo. | [123] |
| Sorafenib/Dihydroartemisinin | A low density lipoprotein receptor -functionalized lipid nanoparticle. | Chemotherapy/PDT | Strong antitumor response and inhibited tumor growth were observed in lipid nanoparticle-treated xenograft tumor models. | [144] |
| Sorafenib/Chlorin e6 | A carrier-free multifunctional nanoparticle. | Chemotherapy/PDT | This nanoparticle could effectively cut off the tumor blood vessels and kill cancer cells simultaneously at a rather low dosage (200 μg/kg) in vivo. | [124] |
| Sorafenib/IR780 iodide | A GPC3 targeting peptide-modified liposome. | Chemotherapy/PDT | This liposomal nanosystem showed imaging ability and synergistic precise antitumor effect in vivo with marked tumor suppression. | [130] |
| Sorafenib/siRNA | PEI-modified liposomes. | Chemotherapy/Gene therapy | Intravenous injection of this liposomal formulation effectively inhibited tumor growth and also increased the survival rates of animals. | [134] |
| Sorafenib/Retinoic acid/miRNA | PEGylated solid lipid nanoparticles were further modified with miRNA. | Chemotherapy/Chemotherapy/Gene therapy | The solid lipid nanoparticles induced significantly enhanced apoptotic effect in gastric cancer cells. In vivo studies clearly showed improved antitumor efficacy of the nanoparticles. | [136] |
| Sorafenib/PEDF gene | PEG-PLGA based nanoparticles | Chemotherapy/Gene therapy | This drug-loading nanoparticle displayed the most effective tumor growth inhibition in the C26 cells and C26-bearing mice as compared to other control groups. | [139] |
synergistic effects of PDT and anti-angiogenic therapy [124]. PTT typically involves the conversion of absorbed light energy into localized heat energy and further induces hyperthermia to kill cancer cells [125]. Nano-based chemo-photothermal therapy has attracted great attention and interest in recent years for enhanced cancer therapy [126,127]. The glypican-3 (GPC3) is highly expressed in most of liver cancers, with intense research and application in targeted delivery of drugs to cancers cells [128,129]. Mu’s group pioneered the development of a GPC3-targeted liposomal theranostic nanoplatorm to co-deliver sorafenib and IR780 iodide for combinatorial chemo-photothermal HCC therapy. Upon irradiation with NIR light, IR780 could absorb the light energy and produce a great amount of localized cytotoxic heat, which enhanced the sensitivity of cancer cells to sorafenib, and subsequently achieved a superior in vivo antitumor effect with marked tumor suppression (Fig. 12) [130].

4.4. Composite nanosystems of sorafenib with gene-therapy agents

As a new model of tumor therapy, gene therapy can restore or enhance the function of immune cells to improve the sensitivity of cancer to immune effects. With high tumor selectivity and biological activity, the gene-therapy agents including small interfering RNA (siRNA), microRNA (miRNA) and CRISPR/Cas9 have gained attractive interest in cancer therapy [131,132]. Co-delivery of sorafenib and siRNA have demonstrated synergistic effect in down-regulating tumor progression–relevant genes expression to provide satisfactory therapeutic effect [70,133]. Polyethyleneimine (PEI) has been considered to be the promising gene carriers due to its unique proton sponge effect for excellent gene transfection efficiency [134]. Sun’s group reported that the co-delivery of sorafenib and siRNA through a PEI-modified liposome could effectively improve the gene transfection efficiency. This liposome was stable in blood circulation and displayed low systemic toxicity due to the dense structure of PEI/siRNA complex. The overexpression of cyclin D1 and GPC3 in cancer cells could be efficiently down-regulated after this liposome administration, which greatly enhanced the sensitivity of tumors to sorafenib-induced therapy [134]. In addition to siRNA, miRNA also plays an important role in cell growth, proliferation and apoptosis [135]. Li et al. selected PEGylated solid lipid nanoparticles to co-deliver sorafenib, all-trans retinoic acid and miRNA into gastric cancer cells. The nanoparticles remarkably inhibited the tumor growth as evidence from the treated-mice showing an obvious reduction of tumor volume [136]. Pigment epithelium-derived factor (PEDF) gene, as an anti-angiogenic agent, was proved to show significant therapeutic effect against many tumors [137,138]. Inspired by this, Chen et al. designed a chemo-gene combination therapy of sorafenib and PEDF gene by using PEG-PLGA nanoparticles as delivery vehicles. The PEG-PLGA polymer with tumor targetability could enhance the drug accumulation of sorafenib and PEDF gene towards tumor tissues and subsequently exhibited significantly improved antitumor efficacy in tumor-bearing mice models [139]. Despite enticing prospects of gene-therapy agents for combination cancer therapy, one of the key concern is their biosafety and more efforts should be paid to understand their biodistribution, excretion pathways, metabolism, degradation and stability in animal models before they are used for combination delivery strategies with sorafenib.

The various composite nanosystems of sorafenib with other agents were summarized in Table 2. The clinical application of current sorafenib-based composite nanosystems is limited due to the issues correlated with toxicity. For most of these systems, their toxicity is multifactorial, depend on composition, physicochemical properties, route of administration and dose. Numerous progress in nanomaterial technology has promoted the development of sorafenib-based combination therapies. In the future days, perhaps we should pay more attention on the illustration of different synergistic mechanisms of sorafenib with other antitumor agents that are necessary to achieve.

Fig. 12 – GPC3-targeted liposomal theranostic nanoplatorms for photothermally enhanced drug delivery. (A) Schematic illustration of the GPC3-targeted nanoplatorms for early diagnosis and combination chemo-photothermal therapy (B) In vivo biodistribution of tumor-bearing mice after different treatments. (C) Ex vivo fluorescent images of tumors after 2 and 4 h of different treatments. Adapted with permission from [130]. Copyright 2019, American Chemical Society.
Table 3 - A summary of common key properties of superior nanodelivery systems.

| Properties            | Characteristics                                                                 | Ref. |
|-----------------------|---------------------------------------------------------------------------------|------|
| Particle size         | The diameter of nanocarriers should be preferably within the range of 10–150 nm, which is beneficial to accumulate drugs in cancer cell by EPR effect. | [145]|
| Surface charge        | The nanocarriers with positive or slight negative charges can be easily internalized into cells. | [145,146]|
| Targetability         | The nanocarriers surface-functionalized with peptides, proteins or antibodies displayed superior targetability to delivering nanoparticles into tumor tissue. | [142]|
| Biodegradability      | The nanocarriers should have complete degradation in the host tissues but without leaving any toxic byproducts. | [141]|
| Biocompatibility      | The nanocarriers and its metabolites in vivo should not induce any negative response, thereby reducing the incidence of side effects. | [147]|
| Biostability          | Nanocarriers should have superior physical and chemical stability for long time circulation in vivo as to maximize its biological functions as delivery vehicles. | [148]|
| Preparation procedure | The nanocarriers should be extracted or synthesized by using safe techniques and convenient procedures. | [147,149]|
| Drug release manner   | The nanocarriers with controlled release manner have better uptake capacity and less toxic side effects. | [150,151]|

5. Conclusion and perspectives

Sorafenib has been recommended as the front-line therapeutic drug by the FDA based on its survival advantages identified in the clinical therapies of liver cancer and kidney cancer. However, the poor pharmacokinetic properties significantly limited the further clinical application in cancer therapy. In order to overcome these limitations, there were various multifunctional nanosized sorafenib delivery systems have been designed and synthesized with the help of nanotechnology. This article summarizes some valuable studies about improving the pharmacokinetic behavior of sorafenib by using natural or synthesized delivery systems and also discusses their preparation technique, physicochemical properties, delivery efficiency and potential advantages or limitations. In addition, this review provides a detailed discussion of the smart sorafenib delivery systems, which aims to improve its specific tumor targetability and tumor microenvironment response. Moreover, in this review, much attention has been paid to overview the nanosystem-based combination therapy of sorafenib with other agents to exhibit synergistic antitumor effect. The overall evidence from the available literatures demonstrated that the application of sorafenib nanoformulations is a facile modality to overcome the disadvantageous events of free sorafenib regimens. However, nanodelivery system of sorafenib is now in the early stage and its applications to deliver sorafenib still suffer from the following challenges: (i) The processing procedures of some nanoformulations involve tedious technique and sophisticated facilities, which may lead to a physical instability and low drug loading efficiency [140]; (ii) The materials used as delivery vehicles may generate some toxic byproducts under its circulation and metabolism in vivo, thereby cause some undesirable systemic side effects [141]; (iii) The nonselective biodistribution of some sorafenib nanoformulations can be observed from in vivo studies, which means that the tissue specificity of some nanoformulations remains to be enhanced [142].

With regard to these challenges, we summarize the common key properties of superior nanosystems in Table 3, and the following several aspects should be considered in future studies to expedite the development of sorafenib nanoformulations. (i) The main purpose of designing sorafenib-based nanodelivery systems is to promote presil drug release into tumor tissues. It is noted that effectively encapsulating sorafenib into nanodelivery systems is still a major problem that should be concerned in order to protect the loaded drug from early leaking through the systemic circulation, thus enhancing drug accumulation at the tumor sites while reducing the side effects. (ii) It is highly desired to translate the laboratory achievements into industrial products. Hence, further studies should focus more attention on exploring safe techniques and convenient procedures of nanocarriers or discovering ideal natural delivery materials, which will significantly help implementation of sorafenib nanoformulations into the drug market. (iii) More efforts should be paid to systematically investigate the biodistribution, pharmacokinetic response and in vivo efficacy of various sorafenib nanoformulations, rather than only be limited to evaluate its inhibition effect against in vitro cancer cells. In this case, more comprehensive preclinical and clinical trials will be conducted to assess the potential value of sorafenib nanoformulations as effective therapeutic modalities for cancer therapy. (iv) Additionally, some literatures have reported that sorafenib can exert synergistic effect with other agents including doxorubicin, ceramide and ursolic acid. Therefore, in future, in-depth studies on combination delivery of sorafenib with other antitumor agents or natural products are needed to be carried out systematically to acquire a better understanding of their joint mechanisms of action, and further reasonably guide their effective combination therapy. To conclude, the overall relevant studies concluded in this review suggest that sorafenib nanoformulations hold great potential and prospects to become viable therapeutics in the clinic by unremitting effort.

Conflict of interest

The authors declare no conflict of interest.
Acknowledgments

This project was supported by the National Natural Science Foundation of China (81972832), Project supported by College Students’ innovation and entrepreneurship training program of Fujian Province (S202010386051).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajps.2020.07.003.

REFERENCES

[1] Wang M, Xu S, Lei H, Wang C, Xiao Z, Jia S, et al. Design, synthesis and antitumor activity of novel sorafenib derivatives bearing pyrazole scaffold. Bioorg Med Chem 2017;25(20):5754–63.

[2] Mangal S, Gao W, Li T, Zhou QT. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin 2017;38(6):782–97.

[3] Chen F, Fang Y, Zhao R, Le J, Zhang B, Huang R, et al. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. Eur J Med Chem 2019;179:916–35.

[4] Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, et al. ICUD-EAU international consultation on kidney cancer 2010: treatment of metastatic disease. Eur Urol 2011;60(4):684–90.

[5] Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted: a population-based study. Lancet Oncol 2012;13(9):927–35.

[6] Iacovelli R, Sternberg CN, Porta C, Verzoni E, de Braud F, Escudier B, et al. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr Drug Targets 2015;16(2):164–70.

[7] Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099–109.

[8] Clark J, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11(15):5472–80.

[9] Chen KF, Tai WT, Hau CY, Huang JW, Liu CY, Chen PJ, et al. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur J Med Chem 2012;55:220–7.

[10] Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 2011;55(5):1041–1048.

[11] Gamero AM, Young HA, Wiltout RH. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 2004;5(2):111–12.

[12] Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7(1):41–51.

[13] Tang K, Luo C, Li Y, Lu C, Zhou W, Huang H, et al. The study of a novel sorafenib derivative HLC-080 as an antimutator agent. PLoS One 2014;9(7):e101889.

[14] Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multitki kinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7(10):3129–40.

[15] Yang S, Zhang B, Gong X, Wang T, Liu Y, Zhang N. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. Int J Nanomedicine 2016;11:2329–43.

[16] Li M, Su Y, Zhang F, Chen K, Xu X, Xu L, et al. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antiimmRNA21 for enhanced hepatocellular carcinoma therapy. Acta Biomater 2018;75:413–26.

[17] Mancuso A, Airolidi A, Viganò R, Pinzello G. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. Dig Liver Dis 2011;43(9):754.

[18] Chen J, Shau HY, Li W, Zhang Z, Kim DH, Lewandowski RJ, et al. Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors. J Control Release 2014;184:10–17.

[19] Thapa RK, Choi JY, Poude BD, Heip TT, Pathak S, Gupta B, et al. Multilayer-coated liquid crystalline nanoparticles for effective sorafenib delivery to hepatocellular carcinoma. ACS Appl Mater Interfaces 2015;7(36):20360–8.

[20] Shahbazi MA, Almeida PV, Correia A, Herranz-Blanco B, Shrestha N, Makila E, et al. Intracarotid responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles. J Control Release 2017;249:111–22.

[21] Fu J, Li W, Xin X, Chen D, Hu H. Transferrin modified nano-liposome co-delivery strategies for enhancing the cancer therapy. J Pharm Sci 2019;108(8):4246–36.

[22] Gao A, Chen B, Gao J, Zhou F, Saeed M, Hou B, et al. Sheddable prodrug vesicles combing adaptive immune resistance for improved photodynamic immunotherapy of cancer. Nano Lett 2020;20(1):353–62.

[23] Hou B, Zhou L, Wang H, Saeed M, Wang D, Xu Z, et al. Engineering stimuli-activatable boolean logic prodrug nanoparticles for combination cancer immunotherapy. Adv Mater 2020;32(12):e1907210.

[24] Wang H, Lu Z, Wang L, Guo T, Wu J, Wan J, et al. New generation nanomedicines constructed from self-assembling small-molecule prodrugs alleviate cancer drug toxicity. Cancer Res 2017;77(24):6963–74.

[25] Han W, Xie B, Li Y, Shi L, Wan J, Chen X, et al. Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer. Theranostics 2019;9(24):7458–73.

[26] Yang F, Jin C, Jiang Y, Li J, Di Y, Ni Q, et al. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev 2011;37(8):633–42.

[27] Schroeder A, Dahlman JE, Sahay G, Love KT, Jiang S, Eltoukhy AA, et al. Alkane-modified short polyethyleneimine for siRNA delivery. J Control Release 2012;160(2):172–6.

[28] Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006;110(2):296–306.
Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm 2007;328(2):191–5.

Jain RA. The manufacturing techniques of various drug loaded biodegradable poly( lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21(23):2475–90.

Gao DY, Lin TT, Sung YC, Liu YC, Chiang WH, Chang CC, et al. CXCR4-targeted lipoid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials 2015;67:194–203.

Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J, et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine 2015;11(9):233–27.

Zhai R, Li TT, Zheng G, Jiang K, Fan L, Shao J. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials 2017;143:1–16.

Kroon J, Metselaar JM, Storm G, van der Pluijm G. Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treat Rev 2014;40(4):578–84.

Liu J, Boonkaw B, Arora J, Mandava SH, Maddox MM, Chava S, et al. Comparison of sorafenib-loaded poly(lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma. J Pharm Sci 2015;104(9):1187–96.

Zhang H, Zhang FM, Yan SJ. Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. Int J Nanomedicine 2012;7:2901–10.

Wang H, Wang H, Yang W, Yu M, Sun S, Xie B. Improved oral bioavailability and liver targeting of sorafenib solid lipid nanoparticles in rats. AAPS PharmSciTech 2018;19(2):761–8.

Lin Ts T, Gao DY, Liu YC, Sung YC, Wan D, Liu JY, et al. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. J Control Release 2016;221:62–70.

Zheng L, Li C, Huang X, Lin X, Lin W, Yang F, et al. Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy. Biomaterials 2019;216:111920.

Su Y, Wang K, Li Y, Song W, Xin Y, Zhao W, et al. Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy. Nanomed (Lond) 2018;13(9):1009–23.

Pellosi DS, Moret F, Fraix A, Marino N, Maiolino S, Gaio E, et al. Pluronic(R)(P123/F127) mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells. Int J Nanomedicine 2016;11:4479–94.

Vishwakarma SK, Sharmila P, Bardia A, Chandrakala L, Raju N, Sravani G, et al. Use of biocompatible sorafenib-gold nanocomposites for reversal of drug resistance in human hepatoblastoma cells. Sci Rep 2015;7(1):8539.

Poojari R, Kini S, Srivastava R, Panda D. Intracellular interactions of electrostatically mediated layer-by-layer assembled polypelectrolytes based sorafenib nanoparticles in oral cancer cells. Colloids Surf B Biointerfaces 2016;143:131–8.

He X, Li J, An S, Jiang C. pH-sensitive drug-delivery systems for tumor targeting. Ther Deliv 2013;4(12):1499–510.

Goenka S, Sant V, Sant S. Graphene-based nanomaterials for drug delivery and tissue engineering. J Control Release 2014;173:75–88.

Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14(3):198–206.

Wang J, Wang H, Li J, Liu Z, Xie H, Wei X, et al. IRGD-decorated polymeric nanoparticles for the efficient delivery of vandetanib to hepatocellular carcinoma: preparation and in vitro and in vivo evaluation. ACS Appl Mater Interfaces 2016;8(30):19228–37.

Liu X, Fan R, Lu B, Le Y. Polyepitides micelles composed of methoxy-poly(ethylene glycol)-poly(β-lactam) acid-poly(β-phenylalanine) triblock polymer for sustained drug delivery. Pharmaceutics 2018;10(4).

Li G, Zhao L. Sorafenib-loaded hydroxethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergetic treatment. Drug Deliv 2019;26(1):756–64.

Yao Y, Su Z, Liang Y, Zhang N. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. Int J Nanomedicine 2015;10:6185–6197.

Liu F, Li M, Liu C, Liu Y, Zhang N. PH-sensitive self-assembled carboxymethyl chitosan-modified DNA/polyethylenamine complexes for efficient gene delivery. J Biomed Nanotechnol 2014;10(11):3397–406.

Wang Y, Shen N, Sakurai K, Tang Z. Multi-stimuli-responsive polymeric prodrug for enhanced cancer treatment. Macromol Biosci 2019;19(12):e1900329.

Jia X, He J, Shen L, Chen J, Wei Z, Qin X, et al. Gradient redox-responsive and two-stage rocket-mimetic drug delivery system for improved tumor accumulation and safe chemotherapy. Nano Lett 2019;19(12):8690–700.

Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017;171(2):273–85.

Wang S, Li F, Qiao R, Hu X, Liao H, Chen L, et al. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics. ACS Nano 2018;12(12):12380–92.

Kuppusamy P, Li H, Ilgangovan G, Cardounel AJ, Zweier JL, Yamada K, et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 2002;62(1):307–12.

Cai Z, Da Z, Lin X, Chen Y, Wu M, Wei Z, et al. Glutathione responsive micelles incorporated with semiconducting polymer dots and doxorubicin for cancer photothermal-chemotherapy. Nanotechnology 2017;28(42):425102.

Liu Y, Yang J, Wang X, Liu J, Wang Z, Liu H, et al. In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryl acid) -cystamine hydrochloride-D-alpha-tocopherol succinate. J Biomater Sci Polym Ed 2016;27(17):1729–47.

Tang H, Chen D, Li C, Zheng C, Wu X, Zhang Y, et al. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells. Int J Pharm 2019;572:138782.

Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F, et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics 2019;9(21):6209–23.

Salem N, Kamal I, Al-Maghribi J, Abuzenadah A, Peer-Zaada AA, Qari Y, et al. High expression of matrix metalloproteinases: MMP-2 and MMP-9 predicts poor survival outcome in colorectal carcinoma. Future Oncol 2016;12(3):323–31.

Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141(1):52–67.
[63] Vihinen P, Alä-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005;5(3):203–20.

[64] Shi L, Hu Y, Lin A, Ma C, Zhang C, Su Y, et al. Matrix metalloproteinase responsive nanoparticles for synergistic treatment of colorectal cancer via simultaneous anti-angiogenesis and chemotherapy. Bioconjug Chem 2016;27(12):2943–53.

[65] Alexander A, Ajazuddin KhanJ, Saraf S, Saraf S. Poly(ethylene glycol)-poly(lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications. J Control Release 2015;172(2):715–29.

[66] Qu Y, Wang B, Liu C, Rong X, Chen H, et al. Injectable and thermoresponsive hydrogel and PDLLA electrosprun nanofiber membrane composites for guided spinal fusion. ACS Appl Mater Interfaces 2018;10(5):4462–70.

[67] Grossen P, Witzigmann D, Sieber S, Huwyler J. PEG-PCL-based nanomedicines: a biodegradable drug delivery system and its application. J Control Release 2017;260:46–60.

[68] Yang X, Yang M, Pang B, Vara M, Xia Y. Gold nanomaterials at work in biomedicine. Chem Rev 2015;115(19):10410–10488.

[69] Jung BK, Lee YK, Hong J, Ghandehari H, Yun CO. Mild Hyperthermia induced by gold nanorod-mediated plasmonic photothermal therapy enhances transduction and replication of oncogenic adeno viral gene delivery. ACS Nano 2016;10(1):1053–43.

[70] Chen X, Zhang Q, Li J, Yang M, Zhao N, Xu FJ. Rattle-structured rough nanocapsules with in-situ-formed gold nanorod cores for complementary gene/chemo/photothermal therapy. ACS Nano 2018;12(6):5646–56.

[71] Liu J, Abshire C, Cary R, Sholl AB, Mandava SH, Datta A, et al. Nanotechnology combined therapy: tyrosine kinase-bound gold nanorod and laser thermal ablation produce a synergistic higher treatment response of renal cell carcinoma in a murine model. BJU Int 2017;119(2):342–8.

[72] Ebrahim HM, El-Rouby MN, Morsy ME, Said MM, Ezz MK. The synergistic cytotoxic effect of laser-irradiated gold nanoparticles and sorafenib against the growth of a human hepatocellular carcinoma cell line. Asian Pac J Cancer Prev 2019;20(11):3369–76.

[73] Chunfu Z, Jinquan C, Duanzhi Y, Yongxian W, Yanlin F, Jiaju T. Preparation and radiolabeling of human serum albumin (HSA)-coated magnetite nanoparticles for magnetically targeted therapy. Appl Radiat Isot 2004;61(6):1255–9.

[74] Zhang JY, He B, Qu W, Cui Z, Wang YB, Zhang H, et al. Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo. J Microencapsul 2011;28(6):528–36.

[75] Callaghan C, Peralta D, Liu J, Mandava SH, Maddox M, Dash S, et al. Combined treatment of tyrosine kinase inhibitor-labeled gold nanorod encapsulated albumin with laser thermal ablation in a renal cell carcinoma model. J Pharm Sci 2016;105(1):284–92.

[76] Wu Q, Zhang M, Luo H, Yi T. Self-assembled honokiol-loaded microbubbles in the treatment of ovarian cancer by ultrasound irradiation. J Biomed Nanotechnol 2018;14(10):1796–805.

[77] Lee JY, Crake C, Teo B, Carugo D, de Saint Victor M, Seth A, et al. Ultrasound-enhanced siRNA delivery using magnetic nanoparticle-loaded chitosan-deoxycholic acid nanodroplets. Adv Healthc Mater 2017;6(8).

[78] Yang T, Ming X, Jie L, Wei W, Guangliang H, Manxia L, et al. Ultrasound-triggered nanodroplets for targeted co-delivery of sorafenib/doxorubicin for hepatocellular carcinoma therapy. J Biomed Nanotechnol 2019;15(9):1881–96.

[79] Park W, Chen J, Cho S, Park SJ, Larson AC, Na K, et al. Acidic pH-triggered drug-eluting nanocomposites for magnetic resonance imaging-monitored intra-arterial drug delivery to hepatocellular carcinoma. ACS Appl Mater Interfaces 2016;8(20):12711–19.

[80] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149(5):1060–72.

[81] Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015;520(7545):57–62.

[82] Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014;156(1–2):317–31.

[83] Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenal PEs navigate cells to ferroptosis. Nat Chem Biol 2017;13(1):81–90.

[84] Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F, et al. BHQ-cyanine-based “Off-On” long-circulating assembly as a ferroptosis amplifier for cancer treatment: a lipid-peroxidation burst device. ACS Appl Mater Interfaces 2019;11(46):42873–84.

[85] Liu T, Liu W, Zhang M, Yu W, Gao F, Li C, et al. Ferrous-supply-regeneration nanoengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. ACS Nano 2018;12(12):12181–92.

[86] Xiao Y, Liu Y, Yang S, Zhang B, Wang T, Jiang D, et al. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloids Surf B Interfaces 2016;141:83–92.

[87] Grillole A, Riva ER, Mondini A, Forte C, Calucci L, Innocenti C, et al. Active Targeting of sorafenib: preparation, characterization, and in vitro testing of drug-loaded magnetic solid lipid nanoparticles. Adv Healthc Mater 2015;4(11):1681–90.

[88] Agarwal A, Saraf S, Asthana A, Gupta U, Gajbhiye V, Jain NK. Lipid based dendritic systems for tumor targeting. Int J Pharm 2008;350(1–2):1–13.

[89] Zhang L, Gong F, Zhang F, Ma J, Zhang P, Shen J. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. Int J Nanomedicine 2013;8:1517–24.

[90] Fan Q, Cheng K, Hu X, Ma X, Zhang R, Yang M, et al. Transferring biomarker into molecular probe: melanin nanoparticle as a naturally active platform for multimodality imaging. J Am Chem Soc 2014;136(43):15185–94.

[91] Zhang R, Fan Q, Yang M, Cheng K, Lu X, Zhang L, et al. Engineering melanin nanoparticles as an efficient drug-delivery system for imaging-guided chemotherapy. Adv Mater 2015;27(94):5063–9.

[92] Sui J, Cui Y, Cai H, Biao S, Xu Z, Zhou L, et al. Synergistic chemotherapeutic effect of sorafenib-loaded pululin-Dox conjugate nanoparticles against murine breast carcinoma. Nanoscale 2017;9(8):2755–67.

[93] Wang JL, Xi Y, Liu YL, Wang ZH, Zhang Q. Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocytotoxic and sorafenib. Invest Ophthalmol Vis Sci 2013;54(13):7983–9.

[94] Babos G, Biro E, Meizcinger M, Feczko T. Dual drug delivery of sorafenib and doxorubicin from PLGA and PEG-PLGA polymer nanoparticles. Polym (Basel) 2018;10(8).

[95] Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with...
doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 2016;64(5):1090–8.

[96] Xiong Q, Cui M, Yu G, Wang J, Song T. Facile fabrication of reduction-responsive supramolecular nanosystems for co-delivery of doxorubicin and sorafenib toward hepatoma cells. Front Pharmacol 2018;9:61.

[97] Malavizhi GL, Retnakumari AP, Nair S, Koyakutty M. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomedicine 2014;10(8):1649–59.

[98] Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett 2019;24:40.

[99] Yang YC, Cai J, Yin J, Zhang J, Wang KJ, Zhang ZT. Hepatin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in glaucic cancers. Carbohydr Polym 2016;136:782–90.

[100] Qhattul HS, Hye T, Alali A, Liu X. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano 2014;8(6):5423–40.

[101] Lei M, Ma G, Sha S, Wang X, Feng H, Zyu Y, et al. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance. Drug Deliv 2019;26(1):262–72.

[102] Yin X, Xiao Y, Han L, Zhang B, Wang T, Su Z, et al. Ceramide-fabricated co-loaded liposomes for the synergetic treatment of hepatocellular carcinoma. AAPS PharmSciTech 2018;19(5):2133–43.

[103] Zhang W, Cai J, Wu B, Shen Z. pH-responsive hyaluronid acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma. J Biomater Appl 2019;34(2):219–28.

[104] Willenbacher E, Khan SZ, Mujica SCA, Trapani D, Hussain S, Wolf D, et al. Curcumin: new insights into an ancient ingredient against cancer. Int J Mol Sci 2019;20(8).

[105] Cao H, Wang Y, He X, Zhang Z, Yin Q, Chen Y, et al. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm 2015;12(9):922–31.

[106] D’Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J Control Release 2015;203:126–39.

[107] Tanki L, Kulhari H, Vadithie LN, Kuncha M, Bhargava S, Pooja D, et al. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment. Eur J Pharm Sci 2019;137:104978.

[108] Saeed M, Gao J, Shi Y, Lammers T, Yu H. Engineering nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy. Theranostics 2019;9(26):7981–8000.

[109] Lu LC, Lee YH, Chang CJ, Shu CN, Fang CY, Shao YY, et al. Increased expression of prostate-specific antigen death-ligand 1 in infiltrating immune cells in hepatocellular carcinoma tissues after sorafenib treatment. Liver Cancer 2019;8(2):110–20.

[110] Chen Y, Ramjiawar RR, Reiberger T, Ng MR, Hato T, Huang Y, et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 2015;61(5):1591–602.

[111] Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 2014;59(4):1435–47.

[112] Chen Y, Liu YC, Sung YC, Ramjiawar RR, Lin TT, Chang CC, et al. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep 2017;7:44123.

[113] Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics 2018;8(4):894–905.

[114] Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm 2016;2016:6058147.

[115] Degroote H, Van Dierendonck A, Geerts A, Van Vlierberge H, Devisscher L. Preclinical and clinical therapeutic strategies affecting tumor-associated macrophages in hepatocellular carcinoma. J Immunol Res 2018;2018:7819520.

[116] Wang T, Zhang J, Hou T, Yin X, Zhang N. Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoinmunotherapy. Nanoscale 2019;11(29):15934–46.

[117] Alsaba HO, Sau S, Alzhani RM, Cheriyani VT, Polin LA, Vaishampayan U, et al. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 2018;183:280–94.

[118] Zhao C, Tong Y, Li X, Shao L, Chen L, Lu J, et al. Photosensitive nanoparticles combining vascular-independent intratumor distribution and on-demand oxygen-depot delivery for enhanced cancer photodynamic therapy. Small 2018;14(2):e1703045.

[119] Gilson RC, Black KCL, Lane DD, Achillefu S. Hybrid TiO2-ruthenium nano-photosensitizer synergistically produces reactive oxygen species in both hypoxic and normoxic conditions. Angew Chem Int Ed Engl 2017;56(36):10717–20.

[120] Zhuang X, Ma X, Xue X, Jiang Q, Song L, Dai L, et al. A photosensitizer-loaded DNA origami nanosystem for photodynamic therapy. ACS Nano 2016;10(5):5486–95.

[121] Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL. Inhibition of the Wnt/beta-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Cancer Lett 2016;381(1):58–66.

[122] Gavini J, Dommann N, Jakob M, Keogh A, Bouchez LC, Karkampouna S, et al. Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis 2019;10(10):749.

[123] Wu H, Wang C, Sun J, Sun L, Wan J, Wang S, et al. Self-assembled and self-monitored sorafenib/indocyanine green nanodrug with synergetic antitumor activity mediated by hyperthermia and reactive oxygen species-induced apoptosis. ACS Appl Mater Interfaces 2019;11(47):43996–4006.

[124] Wei Z, Liang P, Xie J, Song C, Tang C, Wang Y, et al. Carrier-free nano-integrated strategy for synergetic cancer anti-angiogenic therapy and phototherapy. Chem Sci 2019;10(9):2778–84.

[125] Zhang C, Wang S, Xiao J, Tan X, Zhu Y, Su Y, et al. Sentinel lymph node mapping by a near-infrared fluorescent heptamethine dye. Biomaterials 2010;31(7):1911–17.

[126] Yang JC, Chen Y, Li YH, Yin XB. Magnetic resonance imaging-guided multi-drug chemotherapy and photothermal synergistic therapy with pH and NIR-stimulation release. ACS Appl Mater Interfaces 2017;9(27):22278–88.
Thapa RK, Choi JY, Poudel BK, Choi HG, Yong CS, Kim JO. Receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy. Int J Nanomedicine 2016;11:2799–813.

Avanesov A, Honeyager SM, Malicki J, Blair SS. The role of glypicans in Wnt inhibitory factor-1 activity and the structural basis of Wif1’s effects on Wnt and Hedgehog signaling. PLoS Genet 2012;8(2):e1002503.

Tang X, Chen L, Li A, Cai S, Zhang Y, Liu X, et al. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv 2018;25(1):1484–94.

Mu W, Jiang D, Mu S, Liang S, Liu Y, Zhang N. Promoting early diagnosis and precise therapy of hepatocellular carcinoma by glycan-3-targeted synergistic chemo-photothermal theranostics. ACS Appl Mater Interfaces 2019;11(26):23591–604.

Morrison C. Alnylam prepares to land first RNAi drug approval. Nat Rev Drug Discov 2018;17(3):156–7.

Khalil IA, Yamada Y, Harashima H. Optimization of siRNA delivery to target sites: issues and future directions. Expert Opin Drug Deliv 2018;15(11):1053–65.

Yao Y, Wang T, Liu Y, Zhang N. Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 2019;47(1):1374–83.

Sun W, Wang Y, Cai M, Lin L, Chen X, Cao Z, et al. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy. Biomater Sci 2017;5(12):2468–79.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;112(2):281–97.

Li T, Zhang Y, Meng YP, Bo LS, Ke WB. miR-542-3p appended sorafenib/All-trans retinoic acid (ATRA)-loaded lipid nanoparticles to enhance the anticancer efficacy in gastric cancers. Pharm Res 2017;34(12):2710–19.

Hou J, Ge C, Cui M, Liu T, Liu X, Tian H, et al. Pigment epithelium-derived factor promotes tumor metastasis through an interaction with laminin receptor in hepatocellular carcinomas. Cell Death Dis 2017;8(8):e2969.

Falero-Perez J, Park S, Sorensen CM, Sheibani N. PEDF expression affects retinal endothelial cell proangiogenic properties through alterations in cell adhesive mechanisms. Am J Physiol Cell Physiol 2017;313(4):C405–20.

Chen Y, Li N, Xu B, Wu M, Yan X, Zhong L, et al. Polymer-based nanoparticles for chemo/gene-therapy: evaluation its therapeutic efficacy and toxicity against colorectal carcinoma. Biomed Pharmacother 2019;118:109257.

Sheng X, Huang T, Qin J, Li Q, Wang W, Deng L, et al. Preparation, pharmacokinetics, tissue distribution and antitumor effect of sorafenib-incorporating nanoparticles in vivo. Oncol Lett 2017;14(5):6163–9.

He Y, Zeng B, Liang S, Long M, Xu H. Synthesis of pH-responsive biodegradable mesoporous silica-calcium phosphate hybrid nanoparticles as a high potential drug carrier. ACS Appl Mater Interfaces 2017;9(51):44402–9.

Kunjappan S, Govindaraj S, Parasuraman P, Sankaranarayanan M, Arunchalam S, Palanisamy P, et al. Design, insilico modelling and functionality study of folate receptor targeted Myricetin -loaded bovine serum albumin nanoparticle formulation for cancer treatment. Nanotechnology 2019.

Pulit-Prociak J, Grabowska A, Chwastowski M, Majka TM, Banach M. Safety of the application of nanosilver and nanogold in topical cosmetic preparations. Colloids Surf B Biointerfaces 2019;183:110416.

Wang Z, Duan X, Lv Y, Zhao Y. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers. Life Sci 2019;239:117013.

Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7(9):771–82.

Xue X, Huang Y, Bo R, Jia B, Wu H, Yuan Y, et al. Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nat Commun 2018;9(1):3653.

Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv 2014;11(8):1183–201.

Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 2015;200:138–57.

Fan L, Zhang B, Xu A, Shen Z, Guo Y, Zhao R, et al. Carrier-free, pure nanodrug formed by the self-assembly of an anticancer drug for cancer immune therapy. Mol Pharm 2018;15(6):2466–78.

Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev 2016;116(4):2602–63.

Hao X, Hu X, Zhang C, Chen S, Li Z, Yang X, et al. Hybrid mesoporous silica-based drug carrier nanostructures with improved degradability by hydroxyapatite. ACS Nano 2015;9(10):9614–25.